High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial

Ematologia, Azienda Ospedaliera S. Giovanni Battista, Corso Bramante 88, 10126 Turin, Italy. uvitolo@molinette.piemonte.it BACKGROUND AND OBJECTIVES: Poor prognosis diffuse large cell lymphoma (DLCL) responds poorly to standard chemotherapy. Randomized studies comparing high-dose chemotherapy with a...

Full description

Saved in:
Bibliographic Details
Published in:Haematologica (Roma) 2005-06, Vol.90 (6), p.793-801
Main Authors: Vitolo, U, Liberati, AM, Cabras, MG, Federico, M, Angelucci, E, Baldini, L, Boccomini, C, Brugiatelli, M, Calvi, R, Ciccone, G, Genua, A, Deliliers, GL, Levis, A, Parvis, G, Pavone, E, Salvi, F, Sborgia, M, Gallo, E, Intergruppo Italiano Linfomi
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antineoplastic Agents - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Cyclophosphamide - administration & dosage
Disease-Free Survival
Epirubicin - administration & dosage
Female
Granulocyte Colony-Stimulating Factor - administration & dosage
Hematologic and hematopoietic diseases
Humans
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma, Large B-Cell, Diffuse - drug therapy
Male
Medical sciences
Melphalan - administration & dosage
Middle Aged
Mitoxantrone - administration & dosage
Prednisone - administration & dosage
Prognosis
Transplantation, Autologous
Vincristine - administration & dosage
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ematologia, Azienda Ospedaliera S. Giovanni Battista, Corso Bramante 88, 10126 Turin, Italy. uvitolo@molinette.piemonte.it BACKGROUND AND OBJECTIVES: Poor prognosis diffuse large cell lymphoma (DLCL) responds poorly to standard chemotherapy. Randomized studies comparing high-dose chemotherapy with autologous stem-cell transplantation (ASCT) against standard chemotherapy have produced conflicting results. Dose-dense chemotherapy with granulocyte colony-stimulating factor (G-CSF) support seems to hold promise. The purpose of this multicenter, randomized trial was to compare failure-free and overall survival in patients with poor prognosis DLCL treated with high-dose sequential (HDS) chemotherapy followed by ASCT or an outpatient dose-dense chemotherapy regimen (MegaCEOP). DESIGN AND METHODS: Between 1996 and 2001, 130 DLCL patients, aged
ISSN:0390-6078
1592-8721